LB Pharmaceuticals

At #SIRS2026, we shared data from NOVA-1, the Phase 2 trial for our investigational therapy LB-102 in #Schizophrenia that underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia. Read more: bit.ly/4t9S4gx $LBRX

We have initiated NOVA-2, a pivotal Phase 3 trial of LB-102, once-daily, oral investigational small molecule being advanced as a potential first benzamide in the U.S. for the treatment of #Schizophrenia & other neuropsychiatric disorders. Learn more: bit.ly/47prSWR $LBRX

We’re looking forward to hosting a satellite symposium at the 2026 Annual Congress of @SIRSGlobal (#SIRS2026). Learn more about the conference: bit.ly/4d5C36C

Excited to announce that Robert Lenz, M.D., Ph.D., has joined our Board of Directors. His neuroscience R&D leadership will help guide the clinical advancement of LB-102 in #Schizophrenia, #BipolarDepression & adjunctive #MajorDepressiveDisorder. More here: bit.ly/4cxGtD5

Members of our leadership team will participate in the following investor events in March: 💡 Investival Showcase USA on March 10 🤝 Leerink Partners Global Healthcare Conference on March 11 🧠 Stifel 2026 Virtual CNS Forum on March 17 Details here: bit.ly/40IzVKv $LBRX

On International Day of Women and Girls in Science, we recognize the women of LB Pharma who represent 65% of our team and advance science with inclusive leadership and diverse perspectives. Learn more about #IDWGIS: bit.ly/4hKylyA #WomenInScience #EveryVoiceinScience

With new funding secured, we intend to explore the potential of our investigational oral small molecule LB-102 as an adjunctive treatment for major depressive disorder in a Phase 2 trial. Learn more: bit.ly/4tBj7CL $LBRX

Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102, an investigational therapy for #BipolarDepression, in a recently initiated Phase 2 trial. Learn more: bit.ly/4qcV0bg

Bold innovation requires purpose-driven people. In our new #LBBold series, we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration, Lauren Stipp, plays an important role in our success. Learn about our team: bit.ly/44IAYwv

We have initiated ILLUMINATE-1, a Phase 2 trial evaluating our investigational oral small molecule, LB-102, in #BipolarDepression. This is an important step in advancing the development program for LB-102 to include mood disorders. Read more: bit.ly/4662RPN $LBRX

Our time at #JPM26 was productive. In addition to many investor and key partner meetings, our CEO, Heather Turner, shared her perspective on our recent IPO, today’s capital markets, and much more. Thank you to all who joined the conversations. Photography credit: Brian Benton

We are pleased to welcome Dr. Minako Pazdera to the LB Pharmaceuticals leadership team as General Counsel. She brings 25+ years of experience in governance, IP, transactions, compliance and will support the continued advancement of LB-102. Read more here: bit.ly/49RGAXa

Check out our CEO, Heather Turner, discussing our progress, including our recent IPO and the continued clinical advancement of LB-102, on @BiotechTV. Thanks, @bradloncar, for the thoughtful conversation on innovation in neuropsychiatric drug development and leadership in biotech!

We will be at @ACNPorg’s #ACNP2026. We look forward to engaging with the #Neuroscience community and discussing progress in advancing innovative treatments for #NeuropsychiatricDisorders, such as our investigational treatment LB-102.

Don’t miss us at #JPM26. Our CEO, Heather Turner, will join @endpts and @ky_lahucik for a fireside chat, @LifeSciEvents and Gabrielle Masson for a panel with alongside industry leaders, and will be busy with meetings and other events throughout the week. See you there!

We welcome Ellen Rose as SVP, Corporate Affairs, and Lindsay Beaupre as SVP, People and Culture, to LB Pharmaceuticals. Their leadership strengthens our team as we advance LB-102 for #NeuropsychiatricDiseases. Read more in our press release: bit.ly/3Ytgi8l

In 2025, we shared topline Phase 2 data, successfully closed an IPO, expanded our team & are poised to initiate schizophrenia and bipolar depression studies in 2026. We thank you for your support & look forward to continued advancement of LB-102 in 2026: bit.ly/4pMbHcR

❄️ Wishing our community a joyful holiday season! Thank you for your support as we advance the development of LB-102 in schizophrenia, bipolar depression & other neuropsychiatric diseases. From all of us at LB Pharma, may your holidays be peaceful & your 2026 filled with hope.

In October, we rang the @Nasdaq closing bell & connected with Kristina Ayanian at Live from MarketSite to talk about our recent IPO, what’s unique about our lead product candidate, LB-102, and what’s ahead for LB Pharma. 🎥 Watch the full interview here: bit.ly/3YdB37D

Later this month, LB Pharmaceuticals will be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of the 2025 Russell indexes reconstitution. Learn more in our press release: bit.ly/48DdlGQ $LBRX